{"id":"cd20","name":"CD20","symbol":"MS4A1","route":"/targets/cd20/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7315","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156738","uniprot":"https://www.uniprot.org/uniprotkb/P11836/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P11836","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2058","open-targets":"https://platform.opentargets.org/target/ENSG00000156738","civic":"https://civicdb.org/genes/931/summary","oncokb":"https://www.oncokb.org/gene/MS4A1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MS4A1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MS4A1","depmap":"https://depmap.org/portal/gene/MS4A1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000156738-MS4A1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/931","omim":"https://www.omim.org/entry/112210"}],"products":[{"id":"azd5492","name":"AZD5492","status":"phase-2","modality":"T-cell engager","route":"/drugs/azd5492/"},{"id":"epcoritamab","name":"Epcoritamab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3)","route":"/drugs/epcoritamab/"},{"id":"glofitamab","name":"Glofitamab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3, 2:1)","route":"/drugs/glofitamab/"},{"id":"ibritumomab-tiuxetan","name":"Ibritumomab tiuxetan","status":"approved","modality":"Radioimmunotherapy (yttrium-90 labelled anti-CD20 antibody)","route":"/drugs/ibritumomab-tiuxetan/"},{"id":"jnj-90014496","name":"JNJ-90014496","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/jnj-90014496/"},{"id":"mosunetuzumab","name":"Mosunetuzumab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3)","route":"/drugs/mosunetuzumab/"},{"id":"obinutuzumab","name":"Obinutuzumab","status":"approved","modality":"Monoclonal antibody (anti-CD20, glycoengineered type II)","route":"/drugs/obinutuzumab/"},{"id":"odronextamab","name":"Odronextamab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3)","route":"/drugs/odronextamab/"},{"id":"ofatumumab","name":"Ofatumumab","status":"approved","modality":"Monoclonal antibody (anti-CD20, fully human IgG1)","route":"/drugs/ofatumumab/"},{"id":"rituximab","name":"Rituximab","status":"approved","modality":"Monoclonal antibody (anti-CD20, chimeric)","route":"/drugs/rituximab/"},{"id":"rondecabtagene-autoleucel","name":"Rondecabtagene autoleucel","status":"phase-3","modality":"CAR-T cell therapy","route":"/drugs/rondecabtagene-autoleucel/"},{"id":"tqb2825","name":"TQB2825","status":"phase-2","modality":"bispecific antibody","route":"/drugs/tqb2825/"},{"id":"zamtocabtagene-autoleucel","name":"Zamtocabtagene autoleucel","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/zamtocabtagene-autoleucel/"}],"trials":[{"id":"epcore-dlbcl-1","name":"EPCORE DLBCL-1","nct":"NCT04628494","phase":"3","status":"mixed"},{"id":"ielsg43","name":"MATRix/IELSG43","nct":"NCT02531841","phase":"3","status":"positive"},{"id":"polargo","name":"POLARGO","nct":"NCT04182204","phase":"3","status":"positive"},{"id":"nct04680052","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","nct":"NCT04680052","phase":"3","status":"active"},{"id":"nct02972840","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","nct":"NCT02972840","phase":"3","status":"active"},{"id":"nct04404283","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","nct":"NCT04404283","phase":"3","status":"active"},{"id":"nct04075292","name":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","nct":"NCT04075292","phase":"3","status":"active"},{"id":"sunmo","name":"SUNMO","nct":"NCT05171647","phase":"3","status":"positive"},{"id":"amplify","name":"AMPLIFY","nct":"NCT03836261","phase":"3","status":"positive"},{"id":"ielsg37","name":"IELSG37","nct":"NCT01599559","phase":"3","status":"positive"},{"id":"starglo","name":"STARGLO","nct":"NCT04408638","phase":"3","status":"mixed"},{"id":"triangle","name":"TRIANGLE","nct":"NCT02858258","phase":"3","status":"positive"},{"id":"nct02970318","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","nct":"NCT02970318","phase":"3","status":"active"},{"id":"cll13-gaia","name":"CLL13 / GAIA","nct":"NCT02950051","phase":"3","status":"positive"},{"id":"sequoia","name":"SEQUOIA","nct":"NCT03336333","phase":"3","status":"positive"},{"id":"shine","name":"SHINE","nct":"NCT01776840","phase":"3","status":"mixed"},{"id":"glow","name":"GLOW","nct":"NCT03462719","phase":"3","status":"positive"},{"id":"inter-b-nhl-ritux-2010","name":"Inter-B-NHL Ritux 2010","nct":"NCT01516580","phase":"3","status":"positive"},{"id":"calgb-50303","name":"Alliance/CALGB 50303","nct":"NCT00118209","phase":"3","status":"negative"},{"id":"augment","name":"AUGMENT","nct":"NCT01938001","phase":"3","status":"positive"},{"id":"cll14","name":"CLL14","nct":"NCT02242942","phase":"3","status":"positive"},{"id":"elevate-tn","name":"ELEVATE-TN","nct":"NCT02475681","phase":"3","status":"positive"},{"id":"flyer","name":"FLYER","nct":"NCT00278421","phase":"3","status":"positive"},{"id":"prima-follicular","name":"PRIMA","nct":"NCT00140582","phase":"3","status":"mixed"},{"id":"nct00718549","name":"A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)","nct":"NCT00718549","phase":"3","status":"completed"},{"id":"murano","name":"MURANO","nct":"NCT02005471","phase":"3","status":"positive"},{"id":"relevance","name":"RELEVANCE","nct":"NCT01476787","phase":"3","status":"mixed"},{"id":"trog-99-03","name":"TROG 99.03","nct":"NCT00115700","phase":"3","status":"positive"},{"id":"gallium","name":"GALLIUM","nct":"NCT01332968","phase":"3","status":"positive"},{"id":"hd18","name":"GHSG HD18","nct":"NCT00515554","phase":"3","status":"positive"},{"id":"goya","name":"GOYA","nct":"NCT01287741","phase":"3","status":"negative"},{"id":"ielsg-19","name":"IELSG-19","nct":"NCT00210353","phase":"3","status":"mixed"},{"id":"lyma","name":"LyMa","nct":"NCT00921414","phase":"3","status":"positive"},{"id":"remarc","name":"REMARC","nct":"NCT01122472","phase":"3","status":"mixed"},{"id":"nct00254163","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","nct":"NCT00254163","phase":"3","status":"completed"},{"id":"resonate","name":"RESONATE","nct":"NCT01578707","phase":"3","status":"positive"},{"id":"nct04529772","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","nct":"NCT04529772","phase":"3","status":"active"},{"id":"nct06363994","name":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","nct":"NCT06363994","phase":"3","status":"recruiting"},{"id":"nct01827605","name":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","nct":"NCT01827605","phase":"3","status":"completed"},{"id":"nct05888493","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","nct":"NCT05888493","phase":"3","status":"active"},{"id":"nct04712097","name":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi","nct":"NCT04712097","phase":"3","status":"active"},{"id":"nct05057494","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","nct":"NCT05057494","phase":"3","status":"active"},{"id":"nct06970743","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","nct":"NCT06970743","phase":"3","status":"active"},{"id":"nct05947851","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","nct":"NCT05947851","phase":"3","status":"recruiting"},{"id":"nct05624554","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","nct":"NCT05624554","phase":"3","status":"active"},{"id":"nct05023980","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","nct":"NCT05023980","phase":"3","status":"active"},{"id":"nct06508658","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","nct":"NCT06508658","phase":"3","status":"active"},{"id":"nct06846671","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","nct":"NCT06846671","phase":"3","status":"recruiting"},{"id":"nct05100862","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom","nct":"NCT05100862","phase":"3","status":"active"},{"id":"nct04224493","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","nct":"NCT04224493","phase":"3","status":"active"},{"id":"nct06091865","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","nct":"NCT06091865","phase":"3","status":"recruiting"},{"id":"nct06911502","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","nct":"NCT06911502","phase":"3","status":"recruiting"},{"id":"nct06084936","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","nct":"NCT06084936","phase":"3","status":"recruiting"},{"id":"nct06428019","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","nct":"NCT06428019","phase":"3","status":"recruiting"},{"id":"nct06717347","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","nct":"NCT06717347","phase":"3","status":"recruiting"},{"id":"nct06943872","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","nct":"NCT06943872","phase":"3","status":"recruiting"},{"id":"nct07188558","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","nct":"NCT07188558","phase":"3","status":"recruiting"},{"id":"nct04002297","name":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl","nct":"NCT04002297","phase":"3","status":"active"},{"id":"nct07226752","name":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","nct":"NCT07226752","phase":"3","status":"active"},{"id":"nct04965493","name":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","nct":"NCT04965493","phase":"3","status":"active"},{"id":"nct06149286","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","nct":"NCT06149286","phase":"3","status":"recruiting"},{"id":"nct06230224","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","nct":"NCT06230224","phase":"3","status":"active"},{"id":"nct06097364","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","nct":"NCT06097364","phase":"3","status":"active"},{"id":"nct06091254","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","nct":"NCT06091254","phase":"3","status":"recruiting"},{"id":"arched","name":"ARCHED","nct":"NCT05820841","phase":"3","status":"active"},{"id":"celestial-tncll","name":"CELESTIAL-TNCLL","nct":"NCT06073821","phase":"3","status":"active"},{"id":"nct06082102","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","nct":"NCT06082102","phase":"3","status":"recruiting"},{"id":"epcore-dlbcl-2","name":"EPCORE DLBCL-2","nct":"NCT05578976","phase":"3","status":"active"},{"id":"fortplus","name":"FORTplus","nct":"NCT05045664","phase":"3","status":"active"},{"id":"nct03150693","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","nct":"NCT03150693","phase":"3","status":"recruiting"},{"id":"mosun-lbt-fl","name":"Mosunetuzumab against rituximab in low tumour burden follicular lymphoma","nct":"NCT06337318","phase":"3","status":"active"},{"id":"mosun-len-mzl","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","nct":"NCT06006117","phase":"3","status":"active"},{"id":"polar-bear","name":"POLAR BEAR","nct":"NCT04332822","phase":"3","status":"active"},{"id":"nct06220032","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","nct":"NCT06220032","phase":"3","status":"recruiting"},{"id":"prima-cns","name":"PRIMA-CNS","nct":"NCT06830421","phase":"3","status":"active"},{"id":"nct05371093","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","nct":"NCT05371093","phase":"3","status":"active"},{"id":"nct06191744","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","nct":"NCT06191744","phase":"3","status":"active"},{"id":"nct05409066","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","nct":"NCT05409066","phase":"3","status":"active"},{"id":"nct04384484","name":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym","nct":"NCT04384484","phase":"3","status":"active"},{"id":"enrich","name":"ENRICH","phase":"2/3","status":"positive"},{"id":"nct04442022","name":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly","nct":"NCT04442022","phase":"2/3","status":"active"},{"id":"nct04980222","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","nct":"NCT04980222","phase":"2","status":"active"},{"id":"nct03888105","name":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat","nct":"NCT03888105","phase":"2","status":"active"},{"id":"rosewood","name":"ROSEWOOD","nct":"NCT03332017","phase":"2","status":"positive"},{"id":"nct01700946","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","nct":"NCT01700946","phase":"2","status":"completed"},{"id":"nct00582166","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","nct":"NCT00582166","phase":"2"},{"id":"nct00186628","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","nct":"NCT00186628","phase":"2","status":"completed"},{"id":"ptld-1","name":"PTLD-1","nct":"NCT00590447","phase":"2","status":"positive"},{"id":"ielsg32","name":"IELSG32","nct":"NCT01011920","phase":"2","status":"positive"},{"id":"nct01497275","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","nct":"NCT01497275","phase":"2"},{"id":"nct00057811","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","nct":"NCT00057811","phase":"2","status":"completed"},{"id":"nct06890884","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","nct":"NCT06890884","phase":"2","status":"recruiting"},{"id":"nct05207670","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","nct":"NCT05207670","phase":"2","status":"active"},{"id":"nct05951959","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","nct":"NCT05951959","phase":"2","status":"active"},{"id":"nct07189065","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","nct":"NCT07189065","phase":"2","status":"recruiting"},{"id":"nct07015242","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","nct":"NCT07015242","phase":"2","status":"recruiting"},{"id":"nct05406401","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","nct":"NCT05406401","phase":"2","status":"active"},{"id":"nct07029737","name":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","nct":"NCT07029737","phase":"2","status":"recruiting"},{"id":"nct05283720","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","nct":"NCT05283720","phase":"2","status":"active"},{"id":"nct05451810","name":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr","nct":"NCT05451810","phase":"2","status":"active"},{"id":"nct06425302","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","nct":"NCT06425302","phase":"2","status":"active"},{"id":"nct06828991","name":"A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP","nct":"NCT06828991","phase":"2","status":"recruiting"},{"id":"nct06854445","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","nct":"NCT06854445","phase":"2","status":"recruiting"},{"id":"nct07288879","name":"DALY II Japan/MB-CART2019.1 for DLBCL","nct":"NCT07288879","phase":"2","status":"recruiting"},{"id":"nct04792489","name":"DALY II USA/ MB-CART2019.1 for DLBCL","nct":"NCT04792489","phase":"2","status":"recruiting"},{"id":"nct04844866","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","nct":"NCT04844866","phase":"2","status":"recruiting"},{"id":"nct02890602","name":"Erythropoietin for Management of Anemia Caused by Chemotherapy","nct":"NCT02890602","phase":"2","status":"completed"},{"id":"nct06806033","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","nct":"NCT06806033","phase":"2","status":"recruiting"},{"id":"nct06252675","name":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","nct":"NCT06252675","phase":"2","status":"recruiting"},{"id":"nct06534437","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","nct":"NCT06534437","phase":"2","status":"recruiting"},{"id":"nct01059786","name":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","nct":"NCT01059786","phase":"2","status":"active"},{"id":"nct06508931","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","nct":"NCT06508931","phase":"2","status":"recruiting"},{"id":"nct05952024","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","nct":"NCT05952024","phase":"2","status":"recruiting"},{"id":"nct06601504","name":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","nct":"NCT06601504","phase":"2","status":"active"},{"id":"nct03458260","name":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","nct":"NCT03458260","phase":"2","status":"completed"},{"id":"nct04895436","name":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","nct":"NCT04895436","phase":"2","status":"recruiting"},{"id":"nct02180711","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","nct":"NCT02180711","phase":"1/2","status":"active"},{"id":"epcore-nhl-1","name":"EPCORE NHL-1","nct":"NCT03625037","phase":"1/2","status":"positive"},{"id":"nct03075696","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","nct":"NCT03075696","phase":"1/2","status":"active"},{"id":"nct04669171","name":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","nct":"NCT04669171","phase":"1/2","status":"recruiting"},{"id":"nct05615974","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","nct":"NCT05615974","phase":"1/2","status":"recruiting"},{"id":"nct03930953","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","nct":"NCT03930953","phase":"1/2","status":"active"},{"id":"nct04246086","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","nct":"NCT04246086","phase":"1/2","status":"active"},{"id":"nct06564038","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","nct":"NCT06564038","phase":"1/2","status":"recruiting"},{"id":"nct05421663","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","nct":"NCT05421663","phase":"1/2","status":"active"},{"id":"nct06090539","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","nct":"NCT06090539","phase":"1/2","status":"recruiting"},{"id":"nct05201248","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","nct":"NCT05201248","phase":"1/2","status":"active"},{"id":"nct05533775","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","nct":"NCT05533775","phase":"1/2","status":"recruiting"},{"id":"nct06542250","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","nct":"NCT06542250","phase":"1/2","status":"recruiting"},{"id":"nct03671018","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","nct":"NCT03671018","phase":"1/2","status":"active"},{"id":"nct04077723","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","nct":"NCT04077723","phase":"1/2","status":"active"},{"id":"nct06634589","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","nct":"NCT06634589","phase":"1/2","status":"recruiting"},{"id":"nct03533283","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","nct":"NCT03533283","phase":"1/2","status":"active"},{"id":"nct06829771","name":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","nct":"NCT06829771","phase":"1/2","status":"recruiting"},{"id":"nct06119685","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","nct":"NCT06119685","phase":"1/2","status":"recruiting"},{"id":"nct04787042","name":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","nct":"NCT04787042","phase":"1/2","status":"recruiting"},{"id":"nct04623541","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","nct":"NCT04623541","phase":"1/2","status":"active"},{"id":"nct04663347","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","nct":"NCT04663347","phase":"1/2","status":"active"},{"id":"nct07284433","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","nct":"NCT07284433","phase":"1/2","status":"recruiting"},{"id":"nct04494503","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","nct":"NCT04494503","phase":"1/2","status":"recruiting"},{"id":"nct05673057","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","nct":"NCT05673057","phase":"1/2","status":"active"},{"id":"nct07520006","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","nct":"NCT07520006","phase":"1/2","status":"recruiting"},{"id":"nct05826535","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","nct":"NCT05826535","phase":"1/2","status":"recruiting"},{"id":"nct04542824","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","nct":"NCT04542824","phase":"1/2","status":"active"}],"pathways":["complement-in-cancer"],"companies":["abbvie","acrotech-biopharma","astrazeneca","biogen","cellogen","dr-reddys","genmab","halozyme","hetero","interius","johnson-johnson","leah-labs","lyell-immunopharma","mabion","miltenyi-biomedicine","novartis","poseida-therapeutics","regeneron","roche-genentech","sino-biopharm","tg-therapeutics"],"keyPapers":["paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026","paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025","paper-amplify-acalabrutinib-venetoclax-nejm-2025","paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025","paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025","paper-elm-2-odronextamab-follicular-ann-oncol-2024","paper-epcore-nhl-1-epcoritamab-jco-2023","paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023","paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022","paper-polarix-polatuzumab-rchp-nejm-2022","paper-elevate-tn-acalabrutinib-lancet-2020","paper-cll14-venetoclax-obinutuzumab-nejm-2019","paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","paper-prima-final-rituximab-maintenance-follicular-jco-2019","paper-murano-venetoclax-rituximab-nejm-2018","paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017","paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017","paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017","paper-prima-rituximab-maintenance-follicular-lancet-2011"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"cd19-car-t","mechanism":"CD19-negative relapse","category":"antigen"},{"class":"anti-cd20","mechanism":"Loss or down-regulation of CD20","category":"antigen"},{"class":"anti-cd20","mechanism":"Trogocytosis (antigen shaving)","category":"antigen"},{"class":"anti-cd20","mechanism":"Effector and complement exhaustion","category":"pharmacology"},{"class":"btk-inhibitor","mechanism":"BTK C481S","category":"on-target"},{"class":"cd3-bispecific","mechanism":"Loss of the tumour-side antigen","category":"antigen"},{"class":"cd3-bispecific","mechanism":"T-cell exhaustion and depletion","category":"pharmacology"},{"class":"cd3-bispecific","mechanism":"Immunosuppressive node","category":"immune-evasion"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}